Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225264 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 458
- Enrollment target
NCT00225264 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 458 participants.
The verdict
NCT00225264, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 458 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the effects of pioglitazone, once daily (QD), versus glimepiride on the amount of thickening of the carotid artery.
Interventions
- DRUG Pioglitazone
- DRUG Glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225264
The ClinicalTrials.gov registry entry for NCT00225264 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT00225264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225264 about?
NCT00225264 is a clinical study titled "Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.". The primary purpose of this study is to compare the effects of pioglitazone, once daily (QD), versus glimepiride on the amount of thickening of the carotid artery.
What is the current status of trial NCT00225264?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 458 participants. The study started on 2003-10. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00225264?
The interventions under investigation include: Pioglitazone (DRUG), Glimepiride (DRUG).
Who is sponsoring clinical trial NCT00225264?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.